Physician profile
Sergey I Genkin
NPI 1942268701
$9,502.47
in general payments reported to CMS, 2019-2025
22 companies · $2,596 in 2025
The $2,596 reported for 2025 was more than what 95% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $849 · 2020: $569 · 2021: $744 · 2022: $1,509 · 2023: $1,215 · 2024: $2,021 · 2025: $2,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,831.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,145.73 | 2019-2025 | Jardiance |
| Amgen INC. | $1,585.77 | 2021-2025 | Repatha, Evenity, Otezla |
| Astrazeneca Pharmaceuticals Lp | $954.71 | 2024-2025 | Breztri, Airsupra |
| Abbvie INC. | $667.95 | 2022-2025 | |
| Lilly USA, LLC | $371.25 | 2024-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $269.76 | 2023 | Verquvo |
| Aimmune Therapeutics, INC. | $249.97 | 2024-2025 | Zenpep |
| Axsome Therapeutics, INC. | $249.25 | 2025 | Symbravo, Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.32 | 2022-2025 | Xifaxan |
| Pharmacosmos Therapeutics INC. | $247.23 | 2021 | |
| Beigene USA, INC. | $150.00 | 2023 | Brukinsa |
| Ardelyx, INC. | $140.05 | 2024 | Ibsrela |
| Beone Medicines USA, INC. | $135.00 | 2025 | Brukinsa |
| Alkermes, INC. | $130.00 | 2024 | Lybalvi |
| Medtronic, INC. | $127.23 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $125.00 | 2025 | |
| Dova Pharmaceuticals | $125.00 | 2021 | |
| Avanir Pharmaceuticals, INC. | $125.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2023 | Dupixent |
| Eisai INC. | $112.03 | 2020 | |
| Genzyme Corporation | $109.42 | 2023 | |
| Novo Nordisk INC | $108.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergey Genkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.